company background image
GYRE logo

Gyre Therapeutics NasdaqCM:GYRE Stock Report

Last Price

US$12.20

Market Cap

US$956.1m

7D

22.1%

1Y

-58.9%

Updated

23 Dec, 2024

Data

Company Financials

Gyre Therapeutics, Inc.

NasdaqCM:GYRE Stock Report

Market Cap: US$956.1m

GYRE Stock Overview

A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. More details

GYRE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Gyre Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gyre Therapeutics
Historical stock prices
Current Share PriceUS$12.20
52 Week HighUS$30.39
52 Week LowUS$8.26
Beta0
1 Month Change8.06%
3 Month Change-10.88%
1 Year Change-58.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO81.28%

Recent News & Updates

Recent updates

A Look At The Fair Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Jun 27
A Look At The Fair Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Shareholder Returns

GYREUS BiotechsUS Market
7D22.1%-3.3%-2.2%
1Y-58.9%-1.9%23.9%

Return vs Industry: GYRE underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: GYRE underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is GYRE's price volatile compared to industry and market?
GYRE volatility
GYRE Average Weekly Movement10.9%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: GYRE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GYRE's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2002593Han Yingwww.gyretx.com

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.

Gyre Therapeutics, Inc. Fundamentals Summary

How do Gyre Therapeutics's earnings and revenue compare to its market cap?
GYRE fundamental statistics
Market capUS$956.06m
Earnings (TTM)-US$88.82m
Revenue (TTM)US$105.03m

10.0x

P/S Ratio

-11.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GYRE income statement (TTM)
RevenueUS$105.03m
Cost of RevenueUS$3.96m
Gross ProfitUS$101.08m
Other ExpensesUS$189.90m
Earnings-US$88.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin96.23%
Net Profit Margin-84.57%
Debt/Equity Ratio0%

How did GYRE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gyre Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution